FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to field of immunology. Claimed is antibody against human CXCR4 or its functional fragment, which are characterised by the fact that they contain light and heavy chains, which each contain 3 respective CDR. Described are versions of nucleic acids for antibody expression; vector for antibody expression, based on said NA, host cell for obtaining antibody, which contains said vector, and method for obtaining antibody, using cell cultivation. Disclosed is pharmaceutical composition, capable of binding human CXCR4 based on antibody. Described is method of screening and/or identification of molecules as anti-viral medications, CXCR4-antagonists.
EFFECT: application of invention provides antibodies, which can be applied in therapy of HIV infection.
13 cl, 22 dwg, 11 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANISED ANTI-CXCR4 ANTIBODIES FOR TREATING CANCER | 2011 |
|
RU2595394C2 |
| ANTI-CXCR4 ANTIBODIES AND USING THEM FOR TREATING CANCER | 2009 |
|
RU2573897C2 |
| I-3859 ANTIBODY APPLICATION FOR CANCER DETECTION AND DIAGNOSTICS | 2012 |
|
RU2636032C2 |
| NEW ANTIBODY TO CXCR4 AND ITS APPLICATION FOR CANCER DETECTION AND DIAGNOSTICS | 2012 |
|
RU2636345C2 |
| ANTI-c-Met ANTIBODY | 2009 |
|
RU2560257C2 |
| NEW ANTIBODY TO c-Met | 2011 |
|
RU2607377C2 |
| HUMANIZED ANTIBODIES SPECIFIC TO ALPHA-ENOLASE AND METHODS FOR USE IN ANTITUMOR THERAPY | 2014 |
|
RU2761662C2 |
| ANTI-CXCR4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | 2014 |
|
RU2675516C2 |
| NEW ANTIBODIES INHIBITING C-MET DIMERISATION AND USING THEM | 2008 |
|
RU2552161C2 |
| ANTI-LAG-3 ANTIBODIES | 2016 |
|
RU2760582C2 |
